Deutsche Bank Aktiengesellschaft Lowers IQVIA (NYSE:IQV) Price Target to $265.00

IQVIA (NYSE:IQVGet Free Report) had its price objective dropped by research analysts at Deutsche Bank Aktiengesellschaft from $270.00 to $265.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Deutsche Bank Aktiengesellschaft’s price target would indicate a potential upside of 26.70% from the stock’s current price.

Other equities research analysts also recently issued reports about the company. Redburn Atlantic assumed coverage on IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. Evercore ISI dropped their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Robert W. Baird decreased their price target on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a report on Friday. UBS Group increased their price objective on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Finally, Truist Financial lowered their target price on IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a report on Monday, October 14th. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $261.24.

Read Our Latest Stock Report on IQV

IQVIA Stock Up 1.6 %

NYSE:IQV opened at $209.16 on Friday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.85 and a current ratio of 0.81. The company has a market capitalization of $38.13 billion, a price-to-earnings ratio of 27.45, a price-to-earnings-growth ratio of 2.01 and a beta of 1.51. IQVIA has a one year low of $181.03 and a one year high of $261.73. The stock has a 50-day simple moving average of $234.31 and a 200 day simple moving average of $229.74.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Hedge funds and other institutional investors have recently bought and sold shares of the business. Canada Pension Plan Investment Board grew its stake in shares of IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after purchasing an additional 211,653 shares during the last quarter. Lazard Asset Management LLC grew its position in IQVIA by 0.9% in the first quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock worth $825,416,000 after buying an additional 30,014 shares during the last quarter. Farallon Capital Management LLC increased its holdings in shares of IQVIA by 3.1% in the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after buying an additional 86,870 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of IQVIA by 3.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock valued at $634,927,000 after acquiring an additional 92,293 shares during the last quarter. Finally, Capital Research Global Investors grew its holdings in shares of IQVIA by 7.2% in the 1st quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after acquiring an additional 143,533 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

(Get Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Recommended Stories

Analyst Recommendations for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.